Effects of omapatrilat on hemodynamics and safety in patients with heart failure

American Journal of Cardiology

Volumn 88, Issue 6, 2001, Pages 657-661

  Klapholz, Marc ^a,c   Thomas, Ignatius ^a   Eng, Calvin ^a   Iteld, Bruce J ^a   Ponce, George A ^a   Niederman, Alan L ^a   Bilsker, Martin ^a   Heywood, J Thomas ^a   Synhorst, David ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; OMAPATRILAT; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEQUENTIAL ANALYSIS; VASCULAR RESISTANCE;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NEW YORK; PROSPECTIVE STUDIES; PYRIDINES; THIAZEPINES;

EID: 0035885017     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01809-4     Document Type: Article

References (8)

1. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
2. Neurohormonal systems during progression of heart failure: A review
3. Effects of omapatrilat in low, normal, and high renin experimental hypertension
4. Steady-state pharmacokinetics and pharmacodynamics of omapatrilat in normotensive subjects
5. Pharmacodynamic effects of multiple doses of omapatrilat in healthy subjects
6. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
7. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial